Title |
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|
---|---|
Published in |
Cancer Cell, April 2016
|
DOI | 10.1016/j.ccell.2016.03.008 |
Pubmed ID | |
Authors |
Elizabeth C. Townsend, Mark A. Murakami, Alexandra Christodoulou, Amanda L. Christie, Johannes Köster, Tiffany A. DeSouza, Elizabeth A. Morgan, Scott P. Kallgren, Huiyun Liu, Shuo-Chieh Wu, Olivia Plana, Joan Montero, Kristen E. Stevenson, Prakash Rao, Raga Vadhi, Michael Andreeff, Philippe Armand, Karen K. Ballen, Patrizia Barzaghi-Rinaudo, Sarah Cahill, Rachael A. Clark, Vesselina G. Cooke, Matthew S. Davids, Daniel J. DeAngelo, David M. Dorfman, Hilary Eaton, Benjamin L. Ebert, Julia Etchin, Brant Firestone, David C. Fisher, Arnold S. Freedman, Ilene A. Galinsky, Hui Gao, Jacqueline S. Garcia, Francine Garnache-Ottou, Timothy A. Graubert, Alejandro Gutierrez, Ensar Halilovic, Marian H. Harris, Zachary T. Herbert, Steven M. Horwitz, Giorgio Inghirami, Andrew M. Intlekofer, Moriko Ito, Shai Izraeli, Eric D. Jacobsen, Caron A. Jacobson, Sébastien Jeay, Irmela Jeremias, Michelle A. Kelliher, Raphael Koch, Marina Konopleva, Nadja Kopp, Steven M. Kornblau, Andrew L. Kung, Thomas S. Kupper, Nicole R. LeBoeuf, Ann S. LaCasce, Emma Lees, Loretta S. Li, A. Thomas Look, Masato Murakami, Markus Muschen, Donna Neuberg, Samuel Y. Ng, Oreofe O. Odejide, Stuart H. Orkin, Rachel R. Paquette, Andrew E. Place, Justine E. Roderick, Jeremy A. Ryan, Stephen E. Sallan, Brent Shoji, Lewis B. Silverman, Robert J. Soiffer, David P. Steensma, Kimberly Stegmaier, Richard M. Stone, Jerome Tamburini, Aaron R. Thorner, Paul van Hummelen, Martha Wadleigh, Marion Wiesmann, Andrew P. Weng, Jens U. Wuerthner, David A. Williams, Bruce M. Wollison, Andrew A. Lane, Anthony Letai, Monica M. Bertagnolli, Jerome Ritz, Myles Brown, Henry Long, Jon C. Aster, Margaret A. Shipp, James D. Griffin, David M. Weinstock |
Abstract |
More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 18 | 42% |
United Kingdom | 3 | 7% |
Spain | 2 | 5% |
Brazil | 1 | 2% |
Germany | 1 | 2% |
Australia | 1 | 2% |
France | 1 | 2% |
Unknown | 16 | 37% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 26 | 60% |
Scientists | 15 | 35% |
Science communicators (journalists, bloggers, editors) | 1 | 2% |
Practitioners (doctors, other healthcare professionals) | 1 | 2% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | <1% |
United States | 1 | <1% |
Australia | 1 | <1% |
Unknown | 249 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 61 | 24% |
Student > Ph. D. Student | 47 | 19% |
Professor > Associate Professor | 21 | 8% |
Student > Master | 16 | 6% |
Other | 14 | 6% |
Other | 40 | 16% |
Unknown | 53 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 64 | 25% |
Agricultural and Biological Sciences | 39 | 15% |
Medicine and Dentistry | 38 | 15% |
Engineering | 9 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 3% |
Other | 29 | 12% |
Unknown | 65 | 26% |